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Abstract
Purpose Abiraterone is the active metabolite of the
pro-drug abiraterone acetate (AA) and a selective inhibitor
of CYP17, a key enzyme in testosterone synthesis, and
improves overall survival in postdocetaxel metastatic cas-
tration-resistant prostate cancer (mCRPC). This open-label,
single-arm phase 1b study was conducted to assess the
effect of AA and abiraterone on the QT interval.
Methods The study was conducted in 33 patients with
mCRPC. Patients received AA 1,000 mg orally once
daily ? prednisone 5 mg orally twice daily. Electrocar-
diograms (ECGs) were collected in triplicate using 12-lead
Holter monitoring. Baseline ECGs were obtained on Cycle
1 Day-1. Serial ECG recordings and time-matched
pharmacokinetic (PK) blood samples were collected over
24 h on Cycle 1 Day 1 and Cycle 2 Day 1. Serial PK blood
samples were also collected over 24 h on Cycle 1 Day 8.
Results After AA administration, the upper bound of the
2-sided 90 % confidence interval (CI) for the mean base-
line-adjusted QTcF change was \10 ms; no patients dis-
continued due to QTc prolongation or adverse events. No
apparent relationship between change in QTcF and abira-
terone plasma concentrations was observed [estimated
slope (90 % CI): 0.0031 (-0.0040, 0.0102)].
Conclusions There is no significant effect of AA plus
prednisone on the QT/QTc interval in patients with
mCRPC.
Keywords Abiraterone acetate  Pharmacokinetics 
QT interval  Castration-resistant prostate cancer  Phase 1
Introduction
Androgen receptor activation and signaling by androgens
originating from other sources or de novo synthesis play an
important role in the progress of castration-resistant
prostate cancer (CRPC) [1, 2]. Inhibiting the systemic
biosynthesis of androgens by targeting 17a-hydroxylase/
C17,20-lyase (CYP17), an enzyme that catalyzes two key
steroid reactions involving CYP17 in the androgen bio-
synthesis pathway, represents a rational therapeutic
approach in the treatment of CRPC [1].
Abiraterone is a selective, potent, and irreversible
inhibitor of CYP17, with an IC50 of 2–4 nM for the
hydroxylase and lyase [3]. Abiraterone acetate (AA; ZY-
TIGA, Janssen Research & Development LLC, United
States), the 3-acetate analog of abiraterone is a pro-drug
[4]. Abiraterone is the predominant active metabolite of
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AA detected in plasma both in preclinical [5] and clinical
studies [6]. AA (ZYTIGA) in combination with predni-
sone is approved in the United States [7], Canada [8], and
Europe [9] for the treatment of metastatic CRPC (mCRPC)
in patients who have received prior chemotherapy con-
taining docetaxel.
The primary objective of this phase 1b study was to
assess the potential effect of AA plus prednisone on the
QT/QTc interval by using pharmacokinetic (PK) and time-
matched electrocardiograms (ECGs) in patients with
mCRPC. The study also assessed PK and safety of AA. The
follow-up period of the study to assess survival is ongoing,
and results of the analyses of all ECGs, PK, and safety data
through C2D2 are presented here.
Methods
Study population
Patients with mCRPC, with progressive disease following
gonadotropin-releasing hormone (GnRH) therapy or sur-
gical castration, with no more than 1 course of prior che-
motherapy, were enrolled. Patients had confirmed
adenocarcinoma of the prostate without neuroendocrine
differentiation or small cell histology; metastatic disease
documented by bone scan, CT or MRI; prostate-specific
antigen (PSA) progression according to Prostate Cancer
Working Group 2 (PCWG2) criteria [10] or radiographic
progression according to Response Evaluation Criteria in
Solid Tumors (RECIST) criteria [11]; testosterone levels
\50 ng/dL (\2.0 nM); Eastern Cooperative Oncology
Group (ECOG) Performance Status score [12] B1; and
adequate hematologic and biochemical indices.
Exclusion criteria were serious or uncontrolled coexis-
tent non-malignant diseases; uncontrolled hypertension;
clinically significant heart disease in the past 6 months;
diagnosis of cardiac arrhythmia with abnormal ECG;
malignancies other than non-melanoma skin cancer; sur-
gery or local prostatic intervention, radiotherapy, or
immunotherapy within 30 days of the first dose; prior
chemotherapy with mitoxantrone or other anthracyclines;
previous treatment with AA or other investigational CYP17
inhibitor or investigational antiandrogens.
This study was conducted in accordance with the ethical
principles originating in the Declaration of Helsinki and in
accordance with ICH Good Clinical Practice guidelines,
applicable regulatory requirements, and in compliance with
the protocol. Written informed consent was obtained from
all patients. The study was approved by the institutional
review board of all participating centers and is registered
on ClinicalTrials.Gov (NCT00910754).
Study design
This open-label, single-arm study had a 14-day screening
period. The treatment period consisted of 28-day treatment
cycles. Patients received AA 1,000 mg (4 9 250 mg tab-
lets) once daily plus prednisone 5 mg tablets twice daily,
beginning on C1D1 (there was no C1D0). Treatment con-
tinued until disease progression.
Serial sets of 3 time-matched ECG measurements using
a 12-lead Holter monitor were obtained over 24 h on C1D-
1 (baseline), and at predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12,
and 24 h postdose on C1D1and C2D1. Twelve-lead ECGs
were interpreted and annotated in random order by a cen-
tral over-reading board-certified cardiologist who was
blinded to time and date of the recording. Blood samples
for PK analysis of abiraterone and AA levels were col-
lected from each patient at predose and at 0.25, 0.5, 1, 1.5,
2, 3, 4, 6, 8, 12, and 24 h postdose on C1D1 and C1D8.
Samples were also collected on C2D1 at predose and 0.5, 1,
1.5, 2, 3, 4, 6, 8, 12, and 24 h postdose. Samples were
time-matched to ECG measurements on C1D1 and C2D1.
Predose samples were also collected on C1D6 and C1D7
to confirm the attainment of steady-state abiraterone
concentration levels. Samples were analyzed using ultra
performance liquid chromatography with tandem mass
spectrometric detection. The standard curve range was 0.200–
200 ng/mL for abiraterone and was 0.200–50 ng/mL for AA.




Heart Rate (HR), PR interval, QRS duration, and QT
interval [using Bazett’s (QTcB = QT/RR1/2) and Frederi-
cia’s correction (QTcF = QT/RR1/3), where QT, RR,
QTcB, and QTcF are expressed in milliseconds] were
measured on each ECG. Each ECG was graded as Normal
(NML), Abnormal, Clinically Insignificant (ACI), or
Abnormal, Potentially Clinically Significant (APCS).
The primary endpoint was the mean maximal change
from baseline in QTcF. Secondary endpoints included
pharmacokinetic–pharmacodynamic interactions and pro-
portion of patients with change from baseline QTc [ 30 ms
or[60 ms at any time after first dose of study drug.
Pharmacokinetic evaluations
Maximum plasma concentration (Cmax); time to reach Cmax
(tmax); area under the plasma concentration–time curve
(AUC) from 0 to 24 h (AUC24 h) as calculated by the
linear trapezoidal rule for increasing concentrations and the
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logarithmic trapezoidal rule for decreasing concentrations;
accumulation ratio for Cmax (AR Cmax); and accumula-
tion ratio for AUC (AR AUC) were calculated from plasma
concentration–time data for abiraterone using non-com-
partmental analysis with WinNonlin version 5.2.1 (Phar-
sight Corporation, Mountain View, CA, USA).
Statistical methods
The mean maximal QTcF change from baseline in patients
treated with AA is expected to be approximately 7 ms
[standard deviation (SD) of 8.5 ms]. Using a two-sided test
at the 5 % level of significance, a sample size of approx-
imately 34 patients provides 90 % power to detect a QTcF
change from baseline [5 ms.
For all ECG parameters (HR, QTcF, QTcB, PR, QRS,
and QT interval) up to C2D2, the two-sided 95 % confi-
dence intervals (CIs) were provided for the mean ECG
parameters and two-sided 90 % CIs were provided for
mean change from baseline. Qualitative variables were
presented as category counts and percentages. The QTcF
was considered prolonged if one of the three criteria
occurred: an increase from baseline in QTcF of[30 ms but
\60 ms; a C60 ms increase; and an increase to [500 ms
in QTcF intervals.
Results were analyzed for patients’ response after the
initial dose of AA (C1D1) and then again during steady
state (C2D1). Three sets of categorical descriptions were
performed: summary of the clinical interpretations of the
ECGs (NML, ACI, and APCS) for all ECG time points;
summary of the changes from baseline to all ECG time
points using the following categories for QTcF and QTcB:
B0 ms; [0 ms but \30 ms; C30 ms but \60 ms; or
C60 ms; and finally any QTc of B450 ms; any QTc
[450 ms but B480 ms; any QTc [480 ms but B500 ms;
or any QTc [500 ms.
Summary of PK results was evaluated over the same
time points as ECG extractions after initial dose and at
steady state for correlation between compound concentra-
tion and QTcF readings. To explore any pharmacokinetic–
pharmacodynamic relationship for abiraterone, in addition
to graphical method, a linear mixed-effects model was fit to
the data with change from baseline in QTcF as dependent
variable and abiraterone concentration as a predictor and
subject as a random effect.
Safety evaluations
Safety evaluations included treatment-emergent adverse
events (TEAEs) reported throughout the study, changes in
vital sign measurements, clinical laboratory test results,
and physical examinations.
Results
Baseline demographics and disease characteristics
Thirty-three patients with confirmed diagnosis of mCRPC
were enrolled from June 06, 2009 through November 27,
2009 at 4 centers. Patients had a mean (SD) age of 65
(11.5) years and all were white. The baseline disease
characteristics are given in Table 1. None of the patients
had a left ventricular ejection fraction \50 %.
Pharmacodynamic results
Analysis of QTcF
The mean QTcF changes remained stable on C1D1 (-6.0
to 2.3 ms) and on C2D2 (-11.9 to -1.7 ms) (Table 2).
The upper limit of the 90 % CI of the mean baseline cor-
rected QTcF change at each postdose time point was below
10 ms on C1D1 (maximum of upper limits = 5.4 ms) and
C2D1 (maximum of upper limits = 2.4 ms).
Two patients with normal predose value had a postdose
QTcF value[450 ms. The number of patients with at least
one QTcF value[450 ms but B480 ms were 11 on C1D-1
(baseline), 9 on C1D1, and 7 on C2D1. No patient had a
QTcF [ 480 or[500 ms or a change in QTcF [ 60 ms at
any time point. One patient had a C2D1 predose QTcF
value of 480 ms (an increase of 8.7 ms from time-matched
baseline values). Two patients each had QTcF changes
C30 ms but \60 ms at C1D1 predose and on C2D1.
Heart rate, PR interval, QRS duration,
and changes in ECG status
Heart rate was stable on C1D1and C2D1, with all mean
postdose HR changes being less than or equal to 5 beats per
minute (bpm). The categorical analysis was based on a
normal HR between 60 and 100 bpm (Common Termi-
nology Criteria for Adverse Events [CTCAE] Version 4.0
guidelines). Nineteen patients had HR below 60 bpm at
one or more time points; of these, 10 had normal baseline
values. Nine patients had HR above 100 bpm at one or
more time points; of these, 7 had normal baseline values.
These changes were not clinically significant.
The largest mean change in PR interval on C2D1 was a
2.8 ms (SD of 11.4) increase at 4 h postdose and a 6 ms
(SD of 11.8) decrease at 24 h postdose. For categorical
analysis, PR interval [200 ms but B220 ms was consid-
ered to be ACI, and PR interval[220 ms was considered to
be APCS (CTCAE Version 4.0 guidelines). Three patients
experienced at least one PR interval [200 ms with ECG
status classified as ACI at those time points; of these, 2 had
PR interval [200 ms at baseline and postdose. Two
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patients experienced at least one PR interval[220 ms with
ECG status classified as APCS at their highest postdose PR
reading time points. One patient had an average PR interval
of 207 ms on C1D1 (1 h postdose), but the second ECG in
the serial set of 3 ECGs had a PR reading of 235 ms, which
was considered to be APCS.
The QRS duration was stable after AA administration. On
C2D1, the largest mean increase of 1.0 ms (SD of 4.8) was
observed at 0.5 h, and the largest decrease of -1.8 ms (SD of
4.2) was observed at 1.5 h. For categorical analysis, a QRS
duration B100 ms was considered normal. Fourteen patients
had QRS readings[100 ms at various time points during the
study; of these, 13 had increased QRS duration during both
baseline and postbaseline extractions. None of the patients
had an increase in QRS duration from baseline by C10 % or
an absolute value[120 ms (considered APCS).
Five patients had worsening of condition postdose based
on ECG readings. Three patients with normal ECG predose
experienced at least one instance of ACI classification in
the ECGs postdose (sinus tachycardia or sinus bradycar-
dia). Two patients with ECG readings classified ACI pre-
dose had at least one instance of APCS classification
postdose (sinus bradycardia and first-degree AV block).
Pharmacokinetic results
Since most AA concentrations in plasma were below the
lower limit of quantification, PK analyses were not per-
formed for AA. Peak abiraterone concentrations were
reached at approximately the same time after single and
multiple doses of AA (median, tmax * 2 h). Plasma abi-
raterone concentrations declined in a biphasic manner
(Fig. 1). After a single dose of AA, systemic exposure was
Table 1 Baseline disease characteristics (safety analysis set)
N = 33
Years since diagnosis to first dose
Mean (SD) 8.6 (6.57)
Median (range) 6.7 (1, 32)
Stage at diagnosis, n (%)
Primary tumor (T) stage
T1–T4 23 (69.7 %)
TX 7 (21.2 %)
Unknown/not applicable 3 (9.1 %)
Regional lymph nodes (N) Stage, n (%)
N0–N3 11 (33.3 %)
NX 17 (51.5 %)
Unknown/not applicable 5 (15.2 %)
Metastasis (M) stage at diagnosis, n (%)
M0 8 (24.2 %)
M1 (M1, M1a, M1b, M1c) 15 (45.5 %)
MX 8 (24.2 %)
Unknown/not applicable 2 (6.1 %)
Gleason total score at diagnosis, n (%)
\7 3 (9.1 %)
7a 16 (48.5 %)
[7 11 (33.3 %)
Unknown 3 (9.1 %)
PSA (ng/mL) at initial diagnosisb
Mean (SD) 213.7 (538.28)
Median (range) 11.7 (2, 2183)
Extent of disease, n (%)
Bone only 14 (42.4 %)
Visceral disease only 1 (3.0 %)
Bone and soft tissue (node only) 8 (24.2 %)
Bone and visceral disease 4 (12.1 %)
Bone, soft tissue (node only), and visceral disease 3 (9.1 %)
Soft tissue only (node only) 1 (3.0 %)
Soft tissue (node only) and visceral disease 2 (6.1 %)
ECOG status, n (%)
0 26 (78.8 %)
1 7 (21.2 %)
MUGA scan/echocardiogram, n (%)
Normal 30 (90.9 %)
Abnormal-NCS 3 (9.1 %)
Prior chemotherapy, n (%)
Yes 9 (27 %)c
No 24 (73 %)
Prior radiotherapy, n (%)
Yes 23 (70 %)
No 9 (27 %)
Unknown 1 (3 %)
Table 1 continued
N = 33
Prior orchiectomy, n (%)
Yes 5 (15 %)
No 28 (85 %)
Prior therapy with ketoconazole or aminoglutethimide, n (%)
Yes 6 (18 %)
No 27 (82 %)
Number of prior chemotherapies, mean (SD) 1.0 (0.00)
ECOG Eastern Cooperative Oncology Group, MUGA Multi-gated
Acquisition Scan, NCS non-clinically significant, PSA prostate-spe-
cific antigen
a One patient with total Gleason grade of 7 and unknown first and
second Gleason grade is included in this category
b n = 25,
c All 9 patients were on docetaxel
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Cmax: 182 ng/mL and AUC24h: 675 ng h/mL. Systemic
exposure values were comparable after multiple dosing on
C1D8 and C2D1 (Table 3). Mean accumulation ratios were
similar following multiple dosing (Table 3).
Pharmacokinetic–pharmacodynamic relationship
The individual change from baseline in QTcF interval and
corresponding abiraterone plasma concentrations exhibited
no apparent relationship (Fig. 2). No significant correla-
tions were observed between the change from baseline in
QTcF and plasma concentration [estimated slope:
0.0031 ms; 90 % CI (-0.0040, 0.0102)] or between Cmax
and the corresponding change from baseline in QTcF at
individual Tmax [estimated slope: 0.0036 ms; 90 % CI
(-0.0084, 0.0156)]. At mean Cmax (204.1 ng/mL), the
predicted values of mean change from baseline in QTcF
and the associated 90 % CI [-1.99 ms (-5.2387, 1.2542)]
further confirms the lack of correlation. Similar results
were observed for QTcB (Fig. 2).
Safety
Up to C2D2, 20 (61 %) patients reported at least one
TEAE, all of Grade 1 or 2 (Table 4). A single Grade 3
TEAE of increased alkaline phosphatase (884 U/L; not
serious, not drug-related, ongoing) was reported in 1 (3 %)
patient. This patient had bone metastases at the time of
enrollment, with baseline alkaline phosphatase of 378 U/L.
The most commonly reported TEAE was hot flush (Table 4).
Drug-related TEAEs were reported in 12 (36 %) patients,
the most common were dizziness and hot flush in 4 (12 %)
patients each. There were no Grade 4 TEAEs, serious
TEAEs, TEAE leading to discontinuation, or deaths.
Five patients had TEAEs of interest: liver function test
abnormalities [alkaline phosphatase increased (n = 2),
aspartate aminotransferase increased (n = 1), both alkaline
phosphatase and aspartate aminotransferase increased
(n = 1)], hypokalemia (n = 2), and edema (n = 1). Most
patients entered the study with Grade 0 or 1 hematology
and chemistry values, and there were no shifts from Grade
0 or 1 to Grade 3, up to C2D2. Lymphocytopenia was
reported as a Grade 2 abnormality in 3 patients. There were
no reports of Grade 3 or 4 hematologic abnormalities and
Grade 4 chemistry abnormalities.
Discussion
Some of the non-cardiac drugs across diverse therapeutic
classes have been known to delay cardiac repolarization,
resulting in arrhythmias, especially concerning torsade de
Table 2 Summary statistics for change from baseline of QTcF interval (pharmacodynamic analysis set)
Cycle Days Time point N Mean (SD) ms Median ms Min:Max Ms Q1:Q3 ms 90 % CI ms
1 1 Predose 31 1.7 (15.5) -0.3 -30.3:45.7 -8.3:8.0 -3.0:6.4
0.5 32 2.3 (10.1) 2.7 -25.3:23.0 -5.2:9.5 -0.8:5.3
1 32 -0.5 (11.4) -2.0 -18.0:27.7 -9.7:4.8 -4.0:2.9
1.5 32 0.2 (14.3) -0.3 -23.7:27.7 -10.7:11.3 -4.1:4.5
2 32 -1.7 (10.0) -2.0 -20.0:19.0 -8.5:5.3 -4.6:1.3
3 31 -2.9 (12.0) -5.3 -24.3:20.7 -12.7:5.7 -6.5:0.8
4 31 -3.0 (8.0) -1.0 -20.3:11.7 -7.3:2.3 -5.4:-0.6
6 31 1.4 (13.0) 1.0 -35.0:21.7 -7.7:14.7 -2.5:5.4
8 32 -1.4 (13.1) -1.3 -44.0:22.7 -9.3:6.2 -5.3:2.5
12 31 0.3 (11.9) 4.0 -37.7:22.0 -7.0:6.7 -3.4:3.9
24 28 -6.0 (9.7) -5.2 -37.0:6.7 -8.5:-1.2 -9.1:-2.9
2 1 Predose 29 -3.4 (13.2) -3.3 -38.7:18.3 -13.3:6.7 -7.6:0.8
0.5 32 -3.1 (11.8) -3.2 -32.0:18.3 -9.7:5.7 -6.6:0.5
1 33 -1.7 (13.9) 0.0 -31.7:20.3 -11.3:9.0 -5.8:2.4
1.5 33 -4.2 (15.6) -1.0 -37.7:34.0 -13.7:4.0 -8.8:0.4
2 33 -4.7 (12.1) -3.3 -27.0:19.7 -14.0:4.0 -8.3:-1.1
3 33 -5.0 (15.4) -2.0 -42.0:19.0 -15.7:7.3 -9.6:-0.5
4 32 -6.2 (14.4) -5.3 -30.3:28.7 -17.7:3.3 -10.5:-1.9
6 30 -3.1 (17.6) -6.2 -42.0:27.0 -12.0:9.3 -8.6:2.4
8 32 -3.1 (16.0) -6.2 -37.0:35.7 -12.5:7.7 -7.9:1.7
12 33 -2.9 (11.2) -4.7 -21.7:23.3 -9.0:4.3 -6.2:0.4
24 29 -11.9 (14.2) -12.7 -38.0:21.7 -20.7:-3.7 -16.4:-7.4
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pointes [13]. Hence, the International Conference on
Harmonization (ICH) E14 guidelines recommend rigorous
characterization of the effect on the QT/QTc interval, for
all new pharmaceutical agents, as part of their premarket-
ing safety investigations [14]. For this study, a typical
‘‘Thorough QT/QTc Study’’ design, as per the ICH E14
guidelines, was not used for several reasons. First, a su-
pratherapeutic dose could not be administered to patients
because the safety and tolerability of doses exceeding
1,000 mg once daily has not been established. Secondly, a
placebo arm was not possible due to the ethical issues
associated with prolonged dosing of this population with a
placebo.
This study was designed to conform with the ‘‘Intensive
QT Trial’’ design, an alternative design to the typical
‘‘Thorough QT/QTc Study’’ design recommended in ICH
E14 guidelines. This study is unique in its robust design
compared to other Intensive QT Trials as it incorporated a
full-day (over 24 h) time-matched baseline (predose) ECG
time points on C1D-1 (instead of only one single predose
baseline ECG time point) that allows for a comparison to
time-matched ECGs postdose. Additionally, the patients
were dosed to steady state, and ECGs were collected on
C2D1 for analysis. This degree of rigor allows for an
analysis of ECGs to identify drug accumulation effects, if
they exist.
For QT correction, Fridericia’s formula was used, as it
performs better with higher HRs than other formulae [15].
Additionally, as recommended in the ICH E14 guidance
[14], data were also analyzed using Bazett’s formula with
similar results (data not shown).
In this study, no clinically significant changes were seen
in the QTcF with AA treatment. The upper bound of the
two-sided 90 % CI for the baseline-adjusted mean change in
QTcF duration across all postdose time points was below
10 ms, the suggested threshold of regulatory concern for
non-antiarrhythmic drugs [14]. Neither absolute values nor
changes from baseline in QTcF duration in this study are
considered a clinical concern (i.e., no patient had a
QTcF[ 500 ms or a change in QTcF [ 60 ms at any time
point). Postdose QTcF increase [30 ms but \60 ms repor-
ted in two patients was not considered clinically significant.
Changes in HR, PR interval, and QRS duration were
examined in this study, as these could reflect toxicities due
to autonomic factors. However, the analysis of central
tendency and categorical analysis of mean changes in these
parameters did not show evidence of any clinically sig-
nificant change on treatment with AA. Specifically, the
Fig. 1 Mean (sd) plasma concentration–time profiles of abiraterone
after single and multiple dose administration of abiraterone acetate to
patients with metastatic CRPC. C1D1 = Cycle 1 Day 1; C1D8 =
Cycle 1 Day 8; C2D1 = Cycle 2 Day 1; CRPC = castration-resistant
prostate cancer
Table 3 Mean (SD) pharmacokinetic parameters following single-
dose administration of abiraterone acetate (pharmacokinetic analysis
set)
Parameter Cycle 1 Day 1
(N = 33)
Cycle 1 Day 8
(N = 33)
Cycle 2 Day 1
(N = 33)
Cmax (ng/mL) 182 (254) 207 (142) 226 (178)
tmax (h) 2 (1–4) 2 (1–4) 2 (1–6)
AUC24h
(ng h/mL)
675 (725) 965 (520) 993 (639)
AR Cmax – 1.8 (1.8) 2.0 (2.4)
AR AUC – 2.0 (1.5) 2.2 (2.3)
AR accumulation ratio, AUC24h area under the plasma concentration–
time curve from time 0 to 24 h postdose, Cmax maximum plasma
concentration
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lack of any clinically significant change in HR post-AA
administration indicates that it is likely that both QTcF and
QTcB data are not significantly affected by the changes in
HR in this study. None of the patients had an increase in
QRS duration from baseline by C10 % or an absolute value
[120 ms.
Exposure increased after multiple dosing of AA com-
pared with exposure after a single dose. The accumulation
ratios following multiple dosing were similar. Steady-state
concentrations appeared to have been reached after 1 week,
as the accumulation ratios on C1D8 was similar to the
accumulation ratios on C2D1. Maximum plasma concen-
trations were reached at a median tmax of 2 h. No
relationship between change from baseline in QTcF and
abiraterone plasma concentrations was observed. Similar
results were observed for QTcB.
No deaths or serious TEAEs were reported through
C2D2. All TEAEs were of Grade 1 or 2, except one Grade
3 TEAE of increased alkaline phosphatase. The toxicity
grades of TEAEs observed are consistent with those
reported in phase 2 and phase 3 studies with AA and
prednisone [16, 17]. Up to C2D2, hypokalemia occurred in
2 patients, peripheral edema occurred in 1 patient, and
there were no reports of hypertension. As the study popu-
lation was entirely white, applicability of the study finding
to other races is limited.
Fig. 2 Scatter plot of plasma
concentration of abiraterone
versus change from baseline in
QTcF and QTcB on day 1 of
Cycles 1 and 2. The reference
line for change in QTcF and
QTcB was based on a linear
mixed-effects model QTcF:
intercept = -2.7015
(P = 0.0214) and
slope = 0.0031 ms
(P = 0.4737). QTcB:
intercept = -3.4726
(P = 0.0124) and
slope = 0.0064 ms
(P = 0.1481)
Cancer Chemother Pharmacol (2012) 70:305–313 311
123
Conclusions
There is no significant effect of AA plus prednisone on the
cardiac QT/QTc interval using time-matched ECGs and
PKs in patients with mCRPC. Systemic exposure to abi-
raterone increased upon multiple dosing. No relationship
between change in QTcF and abiraterone plasma concen-
tration was observed. The results indicate that AA does not
affect the ventricular repolarization in humans to an extent
that would impact risk–benefit considerations. AA plus
prednisone treatment was generally well tolerated, and
safety results were consistent with previous studies.
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